208 related articles for article (PubMed ID: 17083268)
1. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
Smith RD; Yokoyama H; Averill DB; Cooke L; Brosnihan KB; Schiffrin EL; Ferrario CM
Am J Cardiovasc Drugs; 2006; 6(5):335-42. PubMed ID: 17083268
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
Malacco E; Omboni S; Mallion JM; Volpe M;
High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666
[TBL] [Abstract][Full Text] [Related]
4. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Mason RP
Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
[TBL] [Abstract][Full Text] [Related]
5. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
Ewald S; vor dem Esche J; Uen S; Neikes F; Vetter H; Mengden T
Clin Drug Investig; 2006; 26(8):439-46. PubMed ID: 17163276
[TBL] [Abstract][Full Text] [Related]
7. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
Jones MR; Sealey JE; Laragh JH
Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
[TBL] [Abstract][Full Text] [Related]
8. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
[TBL] [Abstract][Full Text] [Related]
9. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
10. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
11. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
12. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
[TBL] [Abstract][Full Text] [Related]
13. Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):255-263. PubMed ID: 28608025
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
Chrysant SG; Chavanu KJ; Xu J
Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
[TBL] [Abstract][Full Text] [Related]
15. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
16. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
17. Role of olmesartan in combination therapy in blood pressure control and vascular function.
Ferrario CM; Smith RD
Vasc Health Risk Manag; 2010 Sep; 6():701-9. PubMed ID: 20859541
[TBL] [Abstract][Full Text] [Related]
18. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
Giles TD; Oparil S; Silfani TN; Wang A; Walker JF
J Clin Hypertens (Greenwich); 2007 Mar; 9(3):187-95. PubMed ID: 17341994
[TBL] [Abstract][Full Text] [Related]
19. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Mallion JM; Heagerty A; Laeis P
J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
